Comparative Safety Profile of the Fixed-Dose Combination Corticosteroid and Long-acting β 2 -Agonist Fluticasone Propionate/Formoterol Fumarate: A 36-Month Longitudinal Cohort Study in UK Primary Care
ConclusionsThe results suggest that FP/FORM was associated with an overall lower adverse outcome rate than the licensed comparators.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Advair | Advair Diskus | Asthma | Corticosteroid Therapy | Databases & Libraries | Drugs & Pharmacology | Flonase | Flovent | Primary Care | Study | Symbicort